Companies Surmodics Inc

Surmodics (SRDX): executive pay, fiscal 2024

Free brief. Every figure links to the company’s own filing.

Velarion Intel: free for 3 days, no card →

Email me Surmodics Inc’s executive pay brief as a PDF

You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.

After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.

CEO total pay$3,665,496CEO Gary Maharaj · source

Say-on-pay support87.66%Latest vote · source

CEO vs. named peers43rd pct.Of 16 peer CEOs

CEO pay, last three years

$3,095,627FY2022
$3,527,263FY2023
$3,665,496FY2024

CEO total pay was $3,665,496 in fiscal 2024, up from $3,527,263 in fiscal 2023.

FY2024: salary $647,481 · bonus $0 · stock awards $940,000 · option awards $1,410,000

Executives and directors

Charles Olson · SVP Gary Maharaj · CEO Teryl Sides · SVP Timothy Arens · CFO Gordon Weber · General Counsel David R. Dantzker, M.D · Independent Director José H. Bedoya · Independent Director Lisa W. Heine · Independent Director Ronald B. Kalich · Former director (through FY2024)Susan E. Knight · Chair of the Board

Frequently asked questions

Who was the highest-paid executive at Surmodics Inc in fiscal 2024?

As disclosed, Gary Maharaj (President and Chief Executive Officer) was the highest-paid executive at Surmodics Inc in fiscal 2024, with total compensation of $3,665,496.

How does Surmodics Inc's chief executive pay compare to its disclosed peer group?

As disclosed, Gary Maharaj's total compensation ranked at the 43rd percentile of Surmodics Inc's disclosed peer group.

How did shareholders vote on Surmodics Inc's executive compensation?

As disclosed, 87.66% of shareholders supported Surmodics Inc's executive compensation in the latest say-on-pay vote.

How much does Surmodics Inc spend in total on board compensation for fiscal 2024?

As disclosed, Surmodics Inc reported total board compensation of $658,250 for fiscal 2024.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table

Named executive officer	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension / NQDC	All other	Total
Gary Maharaj	$647,481	$0	$940,000	$1,410,000	$654,215	$0	$13,800	$3,665,496
President and Chief Executive Officer
Teryl Sides	446,844	0	312,000	468,000	282,182	0	12,344	1,521,370
Senior Vice President and President, Vascular Interventions
Timothy Arens	386,588	0	280,000	420,000	244,130	0	13,793	1,344,511
Senior Vice President of Finance and Information Technology and Chief Financial Officer
Gordon Weber	361,987	0	220,000	330,000	228,595	0	6,113	1,146,695
Senior Vice President of Legal, General Counsel and Secretary
Charles Olson	361,987	0	212,000	318,000	233,301	0	8,827	1,134,115
Senior Vice President and President, Medical Device Coatings

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officer	FY2024 total	FY2023 total	FY2022 total	Δ FY2023→2024
Gary Maharaj	$3,665,496	$3,527,263	$3,095,627	↑ +138,233
Teryl Sides	1,521,370	1,494,375	1,113,022	↑ +26,995
Timothy Arens	1,344,511	1,295,299	1,045,826	↑ +49,212
Gordon Weber	1,146,695	1,102,840	1,019,595	↑ +43,855
Charles Olson	1,134,115	1,118,470	1,023,119	↑ +15,645

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

Our compensation philosophy is performance-based and focuses on aligning the financial interests of our executive officers with those of our shareholders by placing a substantial portion of total compensation 'at risk' while providing overall compensation opportunities that are comparable to market levels.

CEO STI target (% of salary)	80%
CEO LTI target (% of salary)	—
Independent consultant	Pay Governance LLC
Clawback policy	true
Anti-hedging	true
Anti-pledging	true

Equity grants and outstanding awards

Grants of plan-based awards — fiscal year 2024

Executive	Award	Grant date	Threshold	Target	Granted	Maximum	Grant-date fair value
Timothy Arens	RSU	2023-12-04	—	—	8,323	—	$280,000
Gordon Weber	RSU	2023-12-04	—	—	6,539	—	220,000
Charles Olson	RSU	2023-12-04	—	—	6,302	—	212,000
Gary Maharaj	RSU	2023-12-04	—	—	27,942	—	940,000
Teryl Sides	RSU	2023-12-04	—	—	9,274	—	312,000
Gary Maharaj	OPTION	2023-12-04	—	—	89,127	—	1,410,000
Charles Olson	OPTION	2023-12-04	—	—	20,101	—	318,000
Teryl Sides	OPTION	2023-12-04	—	—	29,582	—	468,000
Timothy Arens	OPTION	2023-12-04	—	—	26,548	—	420,000
Gordon Weber	OPTION	2023-12-04	—	—	20,859	—	330,000

Vehicle mix — grant-date fair value by award type

Named executive officer	Time-vested (RSU)	Performance-vested (PSU)	Options / SARs	% performance-vested
Timothy Arens	$280,000	$0	$420,000	0.0%
Gordon Weber	220,000	0	330,000	0.0%
Charles Olson	212,000	0	318,000	0.0%
Gary Maharaj	940,000	0	1,410,000	0.0%
Teryl Sides	312,000	0	468,000	0.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

Outstanding equity awards at fiscal year-end 2024

Executive	Award	Shares unvested	Exercise price	Market value unvested
Timothy Arens	RSU	1,517	—	$58,829
Charles Olson	RSU	1,517	—	58,829
Teryl Sides	RSU	1,517	—	58,829
Gordon Weber	RSU	1,517	—	58,829
Charles Olson	RSU	3,690	—	143,098
Gordon Weber	RSU	3,690	—	143,098
Timothy Arens	Option	4,471	37.44	—
Charles Olson	Option	4,471	37.44	—
Teryl Sides	Option	4,471	37.44	—
Gordon Weber	Option	4,471	37.44	—
Timothy Arens	RSU	4,797	—	186,028
Teryl Sides	RSU	5,535	—	214,647
Gary Maharaj	RSU	6,070	—	235,395
Charles Olson	RSU	6,302	—	244,392
Gordon Weber	RSU	6,539	—	253,582
Timothy Arens	RSU	8,323	—	322,766
Timothy Arens	Option	9,168	43.93	—
Charles Olson	Option	9,168	43.93	—
Teryl Sides	Option	9,168	43.93	—
Gordon Weber	Option	9,168	43.93	—
Teryl Sides	RSU	9,274	—	359,646
Charles Olson	Option	14,432	36.13	—
Gordon Weber	Option	14,432	36.13	—
Gary Maharaj	RSU	16,237	—	629,671
Gordon Weber	RSU	18,123	—	702,809
Gary Maharaj	Option	18,629	37.44	—
Timothy Arens	Option	18,762	36.13	—
Charles Olson	Option	20,101	33.64	—
Gordon Weber	Option	20,859	33.64	—
Teryl Sides	Option	21,648	36.13	—
Timothy Arens	Option	26,548	33.64	—
Gary Maharaj	RSU	27,942	—	1,083,591
Teryl Sides	Option	29,582	33.64	—
Gary Maharaj	Option	36,674	43.93	—
Charles Olson	RSU	39,915	—	2,003,754
Gary Maharaj	RSU	40,093	—	1,554,807
Teryl Sides	RSU	42,502	—	2,605,384
Timothy Arens	RSU	44,275	—	2,306,229
Gary Maharaj	Option	63,502	36.13	—
Gary Maharaj	Option	89,127	33.64	—
Charles Olson	RSU	312,152	—	12,105,238
Gordon Weber	RSU	319,247	—	12,380,378
Timothy Arens	RSU	402,243	—	15,598,986
Teryl Sides	RSU	450,468	—	17,469,125
Gordon Weber	RSU	1,081,800	—	41,952,135
Charles Olson	RSU	1,081,800	—	41,952,145
Timothy Arens	RSU	1,155,320	—	44,803,318
Teryl Sides	RSU	1,335,396	—	51,786,585
Gary Maharaj	RSU	1,374,065	—	53,286,253
Gary Maharaj	RSU	2,977,230	—	115,457,005

Director compensation

Director	Cash fees	Stock awards	Option awards	Non-equity incentive	All other	Total
Susan E. KnightIndependent · Board Chair · Audit (Chair)	$110,000	$62,000	$62,000	—	—	$234,000
David R. Dantzker, M.DIndependent · Organization and Compensation (Chair) · Corporate Governance and Nominating · Audit	70,000	57,500	57,500	—	—	185,000
Lisa W. HeineIndependent · Organization and Compensation · Corporate Governance and Nominating · Audit	66,500	57,500	57,500	—	—	181,500
José H. BedoyaIndependent · Corporate Governance and Nominating (Chair) · Organization and Compensation	61,500	57,500	57,500	—	—	176,500
Ronald B. KalichIndependent · Departed during FY	58,250	57,500	57,500	—	—	173,250
Gary R. MaharajEmployee director	—	—	—	—	—	0

Board fee structure and ownership guideline

Annual cash retainer	$45,000
Annual equity retainer	$115,000
Per board meeting fee	—
Committee chair fees (audit / comp / nom-gov)	20,000 / 15,000 / 10,000
Stock ownership guideline	$5

Total cost of the board

Component	FY2024
Cash retainers and fees	$366,250
Equity awards (grant-date value)	$292,000
All other compensation	$0
Total cost of the board	$658,250

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names Surmodics as a peer

Companies that benchmark against SRDX

10 companies name SRDX as a compensation peer

908 Devices Inc.MASSFY2025
Anika Therapeutics, Inc.ANIKFY2025
Cytek Biosciences, Inc.CTKBFY2025
HARVARD BIOSCIENCE INCHBIOFY2024
LIFECORE BIOMEDICAL, INC. \DE\LFCRFY2025
STANDARD BIOTOOLS INC.LABFY2025
TACTILE SYSTEMS TECHNOLOGY INCTCMDFY2025
TRANSCAT INCTRNSFY2026
ZYNEX INCZYNXFY2024
ZYNEX INCZYXIFY2024

Each company listed discloses SRDX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named SRDX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

Disclosed peer group — fiscal year 2024

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

CERS Cerus CorporationAXGN AxoGen, Inc.LUNG Pulmonx CorporationANIK Anika Therapeutics Inc.OSUR OraSure Technologies, Inc.ATRC AtriCure, Inc.CFMS Conformis, Inc.ATRI Atrion Corp.CUTR Cutera, Inc.SIBN SI-BONE, Inc.AORT Artivion Inc.LMAT LeMaitre Vascular, Inc.TCMD Tactile Systems Technology, Inc.NPCE NeuroPace, Inc.XTNT Xtant Medical Holdings, Inc.CSII Cardiovascular Systems Inc.

Peer reciprocity

The companies Surmodics Inc names as compensation peers that name it back in their own disclosed peer groups.

Anika Therapeutics Inc. (ANIK)¹³⁴LeMaitre Vascular, Inc. (LMAT)¹³⁵Tactile Systems Technology, Inc. (TCMD)¹³⁶

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

Rank	Company	FY	Chief executive	Salary	Stock awards	Option awards	Non-equity incentive	Total
1	AtriCure, Inc.	2025	Michael Carrel	$828,439	$7,203,478	$0	$1,171,703	$9,217,620
2	AxoGen, Inc.	2025	Michael Dale	775,865	7,342,895	0	906,133	9,047,454
3	SI-Bone, Inc.	2025	Laura Francis	685,000	6,038,710	0	729,525	7,453,235
4	Cutera, Inc.	2023	Taylor Harris	271,023	2,747,682	4,250,008	0	7,279,813
5	Artivion Inc.	2025	J. Patrick Mackin	835,145	5,006,990	0	991,368	6,883,108
6	OraSure Technologies, Inc.	2025	Carrie Eglinton Manner	721,000	3,394,188	0	173,040	4,292,228
7	Cerus Corporation	2025	William Greenman	793,750	2,242,585	0	756,000	3,794,657
8	LeMaitre Vascular, Inc.	2025	George LeMaitre	806,347	1,050,000	1,050,000	680,015	3,780,990
9	Surmodics Inc	2024	Gary Maharaj	647,481	940,000	1,410,000	654,215	3,665,496
10	Pulmonx Corporation	2025	Glendon French	116,186	3,224,000	0	0	3,543,520
11	Tactile Systems Technology, Inc.	2025	Sheri Dodd	675,000	2,019,978	0	737,438	3,466,916
12	NeuroPace, Inc.	2025	Joel Becker	567,567	587,340	701,850	551,810	2,408,566
13	Anika Therapeutics Inc.	2025	Stephen Griffin	500,000	1,215,222	0	0	2,033,370
14	Xtant Medical Holdings, Inc.	2025	Sean Browne	624,000	588,812	0	0	1,351,676
15	Atrion Corp.	2023	David Battat	718,077	0	0	180,000	924,464
—	Conformis, Inc.	—	—	—	—	—	—	not in coverage universe
—	Cardiovascular Systems Inc.	—	—	—	—	—	—	not in coverage universe

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Incentive design against the same peers

Company	Annual incentive payout	Long-term vehicle mix	PSU measures include TSR	Compensation consultant
Surmodics Inc	126.3%	Option 60 · Restricted Shares 40	not disclosed	Pay Governance LLC
Anika Therapeutics Inc.	100%	PSU 67 · RSU 33	No	Willis Towers Watson
Artivion Inc.	118.7%	PSU 50 · RSU 50	No	Willis Towers Watson
AtriCure, Inc.	not disclosed	PSU 70 · RSU 30	No	Korn Ferry
Atrion Corp.	25%	RSU 100	not disclosed	FW Cook
AxoGen, Inc.	116.79%	PSU 50 · RSU 50	No	Aon
Cardiovascular Systems Inc.	not disclosed	not disclosed	not disclosed	not disclosed
Cerus Corporation	126%	not disclosed	No	Alpine
Conformis, Inc.	not disclosed	not disclosed	not disclosed	not disclosed
Cutera, Inc.	not disclosed	not disclosed	No	Compensia
LeMaitre Vascular, Inc.	not disclosed	Option 50 · RSU 25 · PSU 25	No	not disclosed
NeuroPace, Inc.	not disclosed	not disclosed	not disclosed	Alpine, Inc.
OraSure Technologies, Inc.	24.0%	RSU 50 · PSU 50	Yes — Relative TSR performance vs peer group	Pay Governance
Pulmonx Corporation	not disclosed	RSU 75 · PRSU 25	not disclosed	Frederic W. Cook & Co., Inc.
SI-Bone, Inc.	106.5%	RSU 50 · PSU 50	Yes — Relative TSR	Compensia, Inc.
Tactile Systems Technology, Inc.	115%	PSU 50 · RSU 50	No	Aon Consulting, Inc.
Xtant Medical Holdings, Inc.	not disclosed	DSU 50 · PSU 50	not disclosed	not disclosed

Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.

Say-on-pay history and pay ratio

Meeting year	Meeting date	For	Against	Abstain	Support	Outcome
2025	2025-02-06	7,415,339	1,043,557	132,993	87.66%	Passed
2024	2024-02-08	9,588,433	650,245	10,353	93.65%	Passed
2023	2023-02-09	11,173,618	669,818	16,655	94.34%	Passed
2022	2022-02-10	11,084,992	591,658	16,826	94.93%	Passed
2021	2021-02-11	11,234,762	274,983	42,478	97.61%	Passed
2020	2020-02-13	10,662,542	296,400	82,208	97.3%	Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting year	Meeting date	Approval — company’s computation
2025	2025-02-06	87.66%^a
2024	2024-02-08	93.65%^b
2023	2023-02-09	94.34%^c

a. Voting standard not stated in the filing.

b. Voting standard not stated in the filing.

c. Voting standard not stated in the filing.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

Insider trades since the proxy

Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

Insider	Role	Transaction date	Code	Shares	Price	Value	Security	Source
Susan E. Knight	Director	2025-01-24	A	7,358	$27	$200,873	Common	Form 4 ↗
Susan E. Knight	Director	2025-01-24	D	7,358	0	0	Derivative, Class A Common	Form 4 ↗
Susan E. Knight	Director	2025-01-24	D	5,266	38	200,898	Common	Form 4 ↗
David Dantzker	Director	2025-02-13	D	5,275	0	0	Derivative, Class A Common	Form 4 ↗
David Dantzker	Director	2025-02-13	D	4,216	34	144,019	Common	Form 4 ↗
David Dantzker	Director	2025-02-13	A	5,275	27	144,008	Common	Form 4 ↗
José H. Bedoya	Director	2025-02-14	D	5,275	0	0	Derivative, Class A Common	Form 4 ↗
José H. Bedoya	Director	2025-02-14	D	4,224	34	144,038	Common	Form 4 ↗
José H. Bedoya	Director	2025-02-14	A	5,275	27	144,008	Common	Form 4 ↗
Lisa W. Heine	Director	2025-02-18	A	2,640	27	72,072	Common	Form 4 ↗
Lisa W. Heine	Director	2025-02-18	D	2,640	0	0	Derivative, Class A Common	Form 4 ↗
Lisa W. Heine	Director	2025-02-18	D	2,115	34	72,100	Common	Form 4 ↗
Charles Olson	SVP, Medical Device Coatings	2025-11-19	D	20,101	0	0	Derivative, Class A Common	Form 4 ↗
Charles Olson	SVP, Medical Device Coatings	2025-11-19	D	19,243	0	0	Derivative, Class A Common	Form 4 ↗
Teryl Sides	SVP, Vascular Interventions	2025-11-19	D	29,582	0	0	Derivative, Class A Common	Form 4 ↗
David Dantzker	Director	2025-11-19	D	40,183	—	—	Common	Form 4 ↗
Teryl Sides	SVP, Vascular Interventions	2025-11-19	D	28,864	0	0	Derivative, Class A Common	Form 4 ↗
Teryl Sides	SVP, Vascular Interventions	2025-11-19	D	17,883	0	0	Derivative, Class A Common	Form 4 ↗
Joseph J. Stich	SVP of HR, President IVD	2025-11-19	D	61,631	—	—	Common	Form 4 ↗
Timothy Arens	Chief Financial Officer	2025-11-19	D	18,337	0	0	Derivative, Class A Common	Form 4 ↗
Susan E. Knight	Director	2025-11-19	D	3,634	0	0	Derivative, Class A Common	Form 4 ↗
David Dantzker	Director	2025-11-19	D	4,674	0	0	Derivative, Class A Common	Form 4 ↗
Teryl Sides	SVP, Vascular Interventions	2025-11-19	D	18,337	0	0	Derivative, Class A Common	Form 4 ↗
Teryl Sides	SVP, Vascular Interventions	2025-11-19	D	12,292	0	0	Derivative, Class A Common	Form 4 ↗
Gordon Weber	Sr. VP of Legal, GC and Sec.	2025-11-19	D	17,883	0	0	Derivative, Class A Common	Form 4 ↗
Gordon Weber	Sr. VP of Legal, GC and Sec.	2025-11-19	D	21,040	—	—	Common	Form 4 ↗
John D. Manders	VP Finance, Corp. Controller	2025-11-19	D	8,155	—	—	Common	Form 4 ↗
Charles Olson	SVP, Medical Device Coatings	2025-11-19	D	10,653	0	0	Derivative, Class A Common	Form 4 ↗
Charles Olson	SVP, Medical Device Coatings	2025-11-19	D	51,478	—	—	Common	Form 4 ↗
Lisa W. Heine	Director	2025-11-19	D	13,978	—	—	Common	Form 4 ↗
Gordon Weber	Sr. VP of Legal, GC and Sec.	2025-11-19	D	20,859	0	0	Derivative, Class A Common	Form 4 ↗
Timothy Arens	Chief Financial Officer	2025-11-19	D	25,016	0	0	Derivative, Class A Common	Form 4 ↗
Timothy Arens	Chief Financial Officer	2025-11-19	D	17,883	0	0	Derivative, Class A Common	Form 4 ↗
Susan E. Knight	Director	2025-11-19	D	3,555	0	0	Derivative, Class A Common	Form 4 ↗
Susan E. Knight	Director	2025-11-19	D	3,196	0	0	Derivative, Class A Common	Form 4 ↗
Timothy Arens	Chief Financial Officer	2025-11-19	D	2,615	0	0	Derivative, Class A Common	Form 4 ↗
Gordon Weber	Sr. VP of Legal, GC and Sec.	2025-11-19	D	19,243	0	0	Derivative, Class A Common	Form 4 ↗
Gordon Weber	Sr. VP of Legal, GC and Sec.	2025-11-19	D	18,337	0	0	Derivative, Class A Common	Form 4 ↗
Gordon Weber	Sr. VP of Legal, GC and Sec.	2025-11-19	D	11,538	0	0	Derivative, Class A Common	Form 4 ↗
Charles Olson	SVP, Medical Device Coatings	2025-11-19	D	800	—	—	Common	Form 4 ↗
Charles Olson	SVP, Medical Device Coatings	2025-11-19	D	13,579	0	0	Derivative, Class A Common	Form 4 ↗
Gary R. Maharaj	Director	2025-11-19	D	45,073	0	0	Derivative, Class A Common	Form 4 ↗
Gary R. Maharaj	Director	2025-11-19	D	192,056	—	—	Common	Form 4 ↗
José H. Bedoya	Director	2025-11-19	D	3,853	0	0	Derivative, Class A Common	Form 4 ↗
José H. Bedoya	Director	2025-11-19	D	4,674	0	0	Derivative, Class A Common	Form 4 ↗
José H. Bedoya	Director	2025-11-19	D	3,555	0	0	Derivative, Class A Common	Form 4 ↗
José H. Bedoya	Director	2025-11-19	D	2,964	0	0	Derivative, Class A Common	Form 4 ↗
José H. Bedoya	Director	2025-11-19	D	4,218	0	0	Derivative, Class A Common	Form 4 ↗
José H. Bedoya	Director	2025-11-19	D	2,605	0	0	Derivative, Class A Common	Form 4 ↗
Gary R. Maharaj	Director	2025-11-19	D	89,127	0	0	Derivative, Class A Common	Form 4 ↗
Gary R. Maharaj	Director	2025-11-19	D	84,669	0	0	Derivative, Class A Common	Form 4 ↗
Gary R. Maharaj	Director	2025-11-19	D	73,349	0	0	Derivative, Class A Common	Form 4 ↗
Gary R. Maharaj	Director	2025-11-19	D	74,515	0	0	Derivative, Class A Common	Form 4 ↗
Gary R. Maharaj	Director	2025-11-19	D	62,674	0	0	Derivative, Class A Common	Form 4 ↗
Joseph J. Stich	SVP of HR, President IVD	2025-11-19	D	20,101	0	0	Derivative, Class A Common	Form 4 ↗
Joseph J. Stich	SVP of HR, President IVD	2025-11-19	D	19,243	0	0	Derivative, Class A Common	Form 4 ↗
Joseph J. Stich	SVP of HR, President IVD	2025-11-19	D	18,337	0	0	Derivative, Class A Common	Form 4 ↗
Joseph J. Stich	SVP of HR, President IVD	2025-11-19	D	17,883	0	0	Derivative, Class A Common	Form 4 ↗
Joseph J. Stich	SVP of HR, President IVD	2025-11-19	D	15,668	0	0	Derivative, Class A Common	Form 4 ↗
Joseph J. Stich	SVP of HR, President IVD	2025-11-19	D	12,292	0	0	Derivative, Class A Common	Form 4 ↗
Timothy Arens	Chief Financial Officer	2025-11-19	D	26,548	0	0	Derivative, Class A Common	Form 4 ↗
Timothy Arens	Chief Financial Officer	2025-11-19	D	15,668	0	0	Derivative, Class A Common	Form 4 ↗
Timothy Arens	Chief Financial Officer	2025-11-19	D	10,653	0	0	Derivative, Class A Common	Form 4 ↗
Timothy Arens	Chief Financial Officer	2025-11-19	D	67,299	—	—	Common	Form 4 ↗
José H. Bedoya	Director	2025-11-19	D	30,008	—	—	Common	Form 4 ↗
Susan E. Knight	Director	2025-11-19	D	4,155	0	0	Derivative, Class A Common	Form 4 ↗
Susan E. Knight	Director	2025-11-19	D	5,040	0	0	Derivative, Class A Common	Form 4 ↗
Susan E. Knight	Director	2025-11-19	D	4,548	0	0	Derivative, Class A Common	Form 4 ↗
Susan E. Knight	Director	2025-11-19	D	37,240	—	—	Common	Form 4 ↗
Lisa W. Heine	Director	2025-11-19	D	3,853	0	0	Derivative, Class A Common	Form 4 ↗
Lisa W. Heine	Director	2025-11-19	D	4,674	0	0	Derivative, Class A Common	Form 4 ↗
Lisa W. Heine	Director	2025-11-19	D	3,555	0	0	Derivative, Class A Common	Form 4 ↗
Lisa W. Heine	Director	2025-11-19	D	2,964	0	0	Derivative, Class A Common	Form 4 ↗
Lisa W. Heine	Director	2025-11-19	D	4,218	0	0	Derivative, Class A Common	Form 4 ↗
Lisa W. Heine	Director	2025-11-19	D	2,605	0	0	Derivative, Class A Common	Form 4 ↗
David Dantzker	Director	2025-11-19	D	3,853	0	0	Derivative, Class A Common	Form 4 ↗
David Dantzker	Director	2025-11-19	D	3,555	0	0	Derivative, Class A Common	Form 4 ↗
David Dantzker	Director	2025-11-19	D	2,964	0	0	Derivative, Class A Common	Form 4 ↗
David Dantzker	Director	2025-11-19	D	4,218	0	0	Derivative, Class A Common	Form 4 ↗
David Dantzker	Director	2025-11-19	D	2,605	0	0	Derivative, Class A Common	Form 4 ↗
Teryl Sides	SVP, Vascular Interventions	2025-11-19	D	15,668	0	0	Derivative, Class A Common	Form 4 ↗
Teryl Sides	SVP, Vascular Interventions	2025-11-19	D	8,356	0	0	Derivative, Class A Common	Form 4 ↗
Teryl Sides	SVP, Vascular Interventions	2025-11-19	D	5,463	0	0	Derivative, Class A Common	Form 4 ↗
Teryl Sides	SVP, Vascular Interventions	2025-11-19	D	34,703	—	—	Common	Form 4 ↗
John D. Manders	VP Finance, Corp. Controller	2025-11-19	D	3,160	0	0	Derivative, Class A Common	Form 4 ↗
John D. Manders	VP Finance, Corp. Controller	2025-11-19	D	4,810	0	0	Derivative, Class A Common	Form 4 ↗
John D. Manders	VP Finance, Corp. Controller	2025-11-19	D	4,584	0	0	Derivative, Class A Common	Form 4 ↗
Dividend-equivalent accruals		2025-11-19	—	3,602	—	—	1 insider, 2 accrual rows
Charles Olson	SVP, Medical Device Coatings	2025-11-19	D	18,337	0	0	Derivative, Class A Common	Form 4 ↗
Charles Olson	SVP, Medical Device Coatings	2025-11-19	D	17,883	0	0	Derivative, Class A Common	Form 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 91 transactions

Insider	Role	Transaction date	Code	Shares	Price	Value	Security	Source
Susan E. Knight	Director	2025-01-24	A	7,358	$27	$200,873	Common	Form 4 ↗
Susan E. Knight	Director	2025-01-24	D	7,358	0	0	Derivative, Class A Common	Form 4 ↗
Susan E. Knight	Director	2025-01-24	D	5,266	38	200,898	Common	Form 4 ↗
David Dantzker	Director	2025-02-13	D	5,275	0	0	Derivative, Class A Common	Form 4 ↗
David Dantzker	Director	2025-02-13	D	4,216	34	144,019	Common	Form 4 ↗
David Dantzker	Director	2025-02-13	A	5,275	27	144,008	Common	Form 4 ↗
José H. Bedoya	Director	2025-02-14	D	5,275	0	0	Derivative, Class A Common	Form 4 ↗
José H. Bedoya	Director	2025-02-14	D	4,224	34	144,038	Common	Form 4 ↗
José H. Bedoya	Director	2025-02-14	A	5,275	27	144,008	Common	Form 4 ↗
Lisa W. Heine	Director	2025-02-18	A	2,640	27	72,072	Common	Form 4 ↗
Lisa W. Heine	Director	2025-02-18	D	2,640	0	0	Derivative, Class A Common	Form 4 ↗
Lisa W. Heine	Director	2025-02-18	D	2,115	34	72,100	Common	Form 4 ↗
Charles Olson	SVP, Medical Device Coatings	2025-11-19	D	20,101	0	0	Derivative, Class A Common	Form 4 ↗
Charles Olson	SVP, Medical Device Coatings	2025-11-19	D	19,243	0	0	Derivative, Class A Common	Form 4 ↗
Teryl Sides	SVP, Vascular Interventions	2025-11-19	D	29,582	0	0	Derivative, Class A Common	Form 4 ↗
David Dantzker	Director	2025-11-19	D	40,183	—	—	Common	Form 4 ↗
Teryl Sides	SVP, Vascular Interventions	2025-11-19	D	28,864	0	0	Derivative, Class A Common	Form 4 ↗
Teryl Sides	SVP, Vascular Interventions	2025-11-19	D	17,883	0	0	Derivative, Class A Common	Form 4 ↗
Joseph J. Stich	SVP of HR, President IVD	2025-11-19	D	61,631	—	—	Common	Form 4 ↗
Timothy Arens	Chief Financial Officer	2025-11-19	D	18,337	0	0	Derivative, Class A Common	Form 4 ↗
Susan E. Knight	Director	2025-11-19	D	3,634	0	0	Derivative, Class A Common	Form 4 ↗
David Dantzker	Director	2025-11-19	D	4,674	0	0	Derivative, Class A Common	Form 4 ↗
Teryl Sides	SVP, Vascular Interventions	2025-11-19	D	18,337	0	0	Derivative, Class A Common	Form 4 ↗
Teryl Sides	SVP, Vascular Interventions	2025-11-19	D	12,292	0	0	Derivative, Class A Common	Form 4 ↗
Gordon Weber	Sr. VP of Legal, GC and Sec.	2025-11-19	D	17,883	0	0	Derivative, Class A Common	Form 4 ↗
Gordon Weber	Sr. VP of Legal, GC and Sec.	2025-11-19	D	21,040	—	—	Common	Form 4 ↗
John D. Manders	VP Finance, Corp. Controller	2025-11-19	D	8,155	—	—	Common	Form 4 ↗
Charles Olson	SVP, Medical Device Coatings	2025-11-19	D	10,653	0	0	Derivative, Class A Common	Form 4 ↗
Charles Olson	SVP, Medical Device Coatings	2025-11-19	D	51,478	—	—	Common	Form 4 ↗
Lisa W. Heine	Director	2025-11-19	D	13,978	—	—	Common	Form 4 ↗
Gordon Weber	Sr. VP of Legal, GC and Sec.	2025-11-19	D	20,859	0	0	Derivative, Class A Common	Form 4 ↗
Timothy Arens	Chief Financial Officer	2025-11-19	D	25,016	0	0	Derivative, Class A Common	Form 4 ↗
Timothy Arens	Chief Financial Officer	2025-11-19	D	17,883	0	0	Derivative, Class A Common	Form 4 ↗
Susan E. Knight	Director	2025-11-19	D	3,555	0	0	Derivative, Class A Common	Form 4 ↗
Susan E. Knight	Director	2025-11-19	D	3,196	0	0	Derivative, Class A Common	Form 4 ↗
Timothy Arens	Chief Financial Officer	2025-11-19	D	2,615	0	0	Derivative, Class A Common	Form 4 ↗
Gordon Weber	Sr. VP of Legal, GC and Sec.	2025-11-19	D	19,243	0	0	Derivative, Class A Common	Form 4 ↗
Gordon Weber	Sr. VP of Legal, GC and Sec.	2025-11-19	D	18,337	0	0	Derivative, Class A Common	Form 4 ↗
Gordon Weber	Sr. VP of Legal, GC and Sec.	2025-11-19	D	11,538	0	0	Derivative, Class A Common	Form 4 ↗
Charles Olson	SVP, Medical Device Coatings	2025-11-19	D	800	—	—	Common	Form 4 ↗
Charles Olson	SVP, Medical Device Coatings	2025-11-19	D	13,579	0	0	Derivative, Class A Common	Form 4 ↗
Gary R. Maharaj	Director	2025-11-19	D	45,073	0	0	Derivative, Class A Common	Form 4 ↗
Gary R. Maharaj	Director	2025-11-19	D	192,056	—	—	Common	Form 4 ↗
José H. Bedoya	Director	2025-11-19	D	3,853	0	0	Derivative, Class A Common	Form 4 ↗
José H. Bedoya	Director	2025-11-19	D	4,674	0	0	Derivative, Class A Common	Form 4 ↗
José H. Bedoya	Director	2025-11-19	D	3,555	0	0	Derivative, Class A Common	Form 4 ↗
José H. Bedoya	Director	2025-11-19	D	2,964	0	0	Derivative, Class A Common	Form 4 ↗
José H. Bedoya	Director	2025-11-19	D	4,218	0	0	Derivative, Class A Common	Form 4 ↗
José H. Bedoya	Director	2025-11-19	D	2,605	0	0	Derivative, Class A Common	Form 4 ↗
Gary R. Maharaj	Director	2025-11-19	D	89,127	0	0	Derivative, Class A Common	Form 4 ↗
Gary R. Maharaj	Director	2025-11-19	D	84,669	0	0	Derivative, Class A Common	Form 4 ↗
Gary R. Maharaj	Director	2025-11-19	D	73,349	0	0	Derivative, Class A Common	Form 4 ↗
Gary R. Maharaj	Director	2025-11-19	D	74,515	0	0	Derivative, Class A Common	Form 4 ↗
Gary R. Maharaj	Director	2025-11-19	D	62,674	0	0	Derivative, Class A Common	Form 4 ↗
Joseph J. Stich	SVP of HR, President IVD	2025-11-19	D	20,101	0	0	Derivative, Class A Common	Form 4 ↗
Joseph J. Stich	SVP of HR, President IVD	2025-11-19	D	19,243	0	0	Derivative, Class A Common	Form 4 ↗
Joseph J. Stich	SVP of HR, President IVD	2025-11-19	D	18,337	0	0	Derivative, Class A Common	Form 4 ↗
Joseph J. Stich	SVP of HR, President IVD	2025-11-19	D	17,883	0	0	Derivative, Class A Common	Form 4 ↗
Joseph J. Stich	SVP of HR, President IVD	2025-11-19	D	15,668	0	0	Derivative, Class A Common	Form 4 ↗
Joseph J. Stich	SVP of HR, President IVD	2025-11-19	D	12,292	0	0	Derivative, Class A Common	Form 4 ↗
Timothy Arens	Chief Financial Officer	2025-11-19	D	26,548	0	0	Derivative, Class A Common	Form 4 ↗
Timothy Arens	Chief Financial Officer	2025-11-19	D	15,668	0	0	Derivative, Class A Common	Form 4 ↗
Timothy Arens	Chief Financial Officer	2025-11-19	D	10,653	0	0	Derivative, Class A Common	Form 4 ↗
Timothy Arens	Chief Financial Officer	2025-11-19	D	67,299	—	—	Common	Form 4 ↗
José H. Bedoya	Director	2025-11-19	D	30,008	—	—	Common	Form 4 ↗
Susan E. Knight	Director	2025-11-19	D	4,155	0	0	Derivative, Class A Common	Form 4 ↗
Susan E. Knight	Director	2025-11-19	D	5,040	0	0	Derivative, Class A Common	Form 4 ↗
Susan E. Knight	Director	2025-11-19	D	4,548	0	0	Derivative, Class A Common	Form 4 ↗
Susan E. Knight	Director	2025-11-19	D	37,240	—	—	Common	Form 4 ↗
Lisa W. Heine	Director	2025-11-19	D	3,853	0	0	Derivative, Class A Common	Form 4 ↗
Lisa W. Heine	Director	2025-11-19	D	4,674	0	0	Derivative, Class A Common	Form 4 ↗
Lisa W. Heine	Director	2025-11-19	D	3,555	0	0	Derivative, Class A Common	Form 4 ↗
Lisa W. Heine	Director	2025-11-19	D	2,964	0	0	Derivative, Class A Common	Form 4 ↗
Lisa W. Heine	Director	2025-11-19	D	4,218	0	0	Derivative, Class A Common	Form 4 ↗
Lisa W. Heine	Director	2025-11-19	D	2,605	0	0	Derivative, Class A Common	Form 4 ↗
David Dantzker	Director	2025-11-19	D	3,853	0	0	Derivative, Class A Common	Form 4 ↗
David Dantzker	Director	2025-11-19	D	3,555	0	0	Derivative, Class A Common	Form 4 ↗
David Dantzker	Director	2025-11-19	D	2,964	0	0	Derivative, Class A Common	Form 4 ↗
David Dantzker	Director	2025-11-19	D	4,218	0	0	Derivative, Class A Common	Form 4 ↗
David Dantzker	Director	2025-11-19	D	2,605	0	0	Derivative, Class A Common	Form 4 ↗
Teryl Sides	SVP, Vascular Interventions	2025-11-19	D	15,668	0	0	Derivative, Class A Common	Form 4 ↗
Teryl Sides	SVP, Vascular Interventions	2025-11-19	D	8,356	0	0	Derivative, Class A Common	Form 4 ↗
Teryl Sides	SVP, Vascular Interventions	2025-11-19	D	5,463	0	0	Derivative, Class A Common	Form 4 ↗
Teryl Sides	SVP, Vascular Interventions	2025-11-19	D	34,703	—	—	Common	Form 4 ↗
John D. Manders	VP Finance, Corp. Controller	2025-11-19	D	3,160	0	0	Derivative, Class A Common	Form 4 ↗
John D. Manders	VP Finance, Corp. Controller	2025-11-19	D	4,810	0	0	Derivative, Class A Common	Form 4 ↗
John D. Manders	VP Finance, Corp. Controller	2025-11-19	D	4,584	0	0	Derivative, Class A Common	Form 4 ↗
John D. Manders	VP Finance, Corp. Controller	2025-11-19	D	1,862	0	0	Derivative, Class A Common	Form 4 ↗
John D. Manders	VP Finance, Corp. Controller	2025-11-19	D	1,740	0	0	Derivative, Class A Common	Form 4 ↗
Charles Olson	SVP, Medical Device Coatings	2025-11-19	D	18,337	0	0	Derivative, Class A Common	Form 4 ↗
Charles Olson	SVP, Medical Device Coatings	2025-11-19	D	17,883	0	0	Derivative, Class A Common	Form 4 ↗

Sources (136 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

Section 01, Gary Maharaj. DEF 14A, filed 2024-12-19. Section “Summary Compensation Table” · page 37. As printed: 3,665,496. View filing ↗
Section 01, Teryl Sides. DEF 14A, filed 2024-12-19. Section “Summary Compensation Table” · page 37. As printed: 1,521,370. View filing ↗
Section 01, Timothy Arens. DEF 14A, filed 2024-12-19. Section “Summary Compensation Table” · page 37. As printed: 1,344,511. View filing ↗
Section 01, Gordon Weber. DEF 14A, filed 2024-12-19. Section “Summary Compensation Table” · page 37. As printed: 1,146,695. View filing ↗
Section 01, Charles Olson. DEF 14A, filed 2024-12-19. Section “Summary Compensation Table” · page 37. As printed: 1,134,115. View filing ↗
Section 03, Timothy Arens RSU. DEF 14A, filed 2024-12-19. Section “Grants of Plan-Based Awards in Fiscal 2024” · grants of plan-based awards table. View filing ↗
Section 03, Gordon Weber RSU. DEF 14A, filed 2024-12-19. Section “Grants of Plan-Based Awards in Fiscal 2024” · grants of plan-based awards table. View filing ↗
Section 03, Charles Olson RSU. DEF 14A, filed 2024-12-19. Section “Grants of Plan-Based Awards in Fiscal 2024” · grants of plan-based awards table. View filing ↗
Section 03, Gary Maharaj RSU. DEF 14A, filed 2024-12-19. Section “Grants of Plan-Based Awards in Fiscal 2024” · grants of plan-based awards table. View filing ↗
Section 03, Teryl Sides RSU. DEF 14A, filed 2024-12-19. Section “Grants of Plan-Based Awards in Fiscal 2024” · grants of plan-based awards table. View filing ↗
Section 03, Gary Maharaj OPTION. DEF 14A, filed 2024-12-19. Section “Grants of Plan-Based Awards in Fiscal 2024” · grants of plan-based awards table. View filing ↗
Section 03, Charles Olson OPTION. DEF 14A, filed 2024-12-19. Section “Grants of Plan-Based Awards in Fiscal 2024” · grants of plan-based awards table. View filing ↗
Section 03, Teryl Sides OPTION. DEF 14A, filed 2024-12-19. Section “Grants of Plan-Based Awards in Fiscal 2024” · grants of plan-based awards table. View filing ↗
Section 03, Timothy Arens OPTION. DEF 14A, filed 2024-12-19. Section “Grants of Plan-Based Awards in Fiscal 2024” · grants of plan-based awards table. View filing ↗
Section 03, Gordon Weber OPTION. DEF 14A, filed 2024-12-19. Section “Grants of Plan-Based Awards in Fiscal 2024” · grants of plan-based awards table. View filing ↗
Section 08, Susan E. Knight. DEF 14A, filed 2024-12-19. Section “Director Compensation”. As printed: 234,000. View filing ↗
Section 08, David R. Dantzker, M.D. DEF 14A, filed 2024-12-19. Section “Director Compensation”. As printed: 185,000. View filing ↗
Section 08, Lisa W. Heine. DEF 14A, filed 2024-12-19. Section “Director Compensation”. As printed: 181,500. View filing ↗
Section 08, José H. Bedoya. DEF 14A, filed 2024-12-19. Section “Director Compensation”. As printed: 176,500. View filing ↗
Section 08, Ronald B. Kalich. DEF 14A, filed 2024-12-19. Section “Director Compensation”. As printed: 173,250. View filing ↗
Section 08, Gary R. Maharaj. DEF 14A, filed 2024-12-19. Section “Director Compensation”. As printed: 0. View filing ↗
Section 02, Susan E. Knight 2025-01-24. Form 4, filed 2025-01-28. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Susan E. Knight 2025-01-24. Form 4, filed 2025-01-28. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Susan E. Knight 2025-01-24. Form 4, filed 2025-01-28. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, David Dantzker 2025-02-13. Form 4, filed 2025-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, David Dantzker 2025-02-13. Form 4, filed 2025-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, David Dantzker 2025-02-13. Form 4, filed 2025-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, José H. Bedoya 2025-02-14. Form 4, filed 2025-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, José H. Bedoya 2025-02-14. Form 4, filed 2025-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, José H. Bedoya 2025-02-14. Form 4, filed 2025-02-18. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Lisa W. Heine 2025-02-18. Form 4, filed 2025-02-20. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Lisa W. Heine 2025-02-18. Form 4, filed 2025-02-20. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Lisa W. Heine 2025-02-18. Form 4, filed 2025-02-20. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Charles Olson 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Charles Olson 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Teryl Sides 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, David Dantzker 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Teryl Sides 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Teryl Sides 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph J. Stich 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Timothy Arens 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Susan E. Knight 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, David Dantzker 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Teryl Sides 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Teryl Sides 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gordon Weber 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gordon Weber 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John D. Manders 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Charles Olson 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Charles Olson 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Lisa W. Heine 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gordon Weber 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Timothy Arens 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Timothy Arens 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Susan E. Knight 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Susan E. Knight 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Timothy Arens 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gordon Weber 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gordon Weber 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gordon Weber 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Charles Olson 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Charles Olson 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gary R. Maharaj 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gary R. Maharaj 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, José H. Bedoya 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, José H. Bedoya 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, José H. Bedoya 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, José H. Bedoya 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, José H. Bedoya 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, José H. Bedoya 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gary R. Maharaj 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gary R. Maharaj 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gary R. Maharaj 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gary R. Maharaj 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Gary R. Maharaj 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph J. Stich 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph J. Stich 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph J. Stich 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph J. Stich 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph J. Stich 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Joseph J. Stich 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Timothy Arens 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Timothy Arens 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Timothy Arens 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Timothy Arens 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, José H. Bedoya 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Susan E. Knight 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Susan E. Knight 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Susan E. Knight 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Susan E. Knight 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Lisa W. Heine 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Lisa W. Heine 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Lisa W. Heine 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Lisa W. Heine 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Lisa W. Heine 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Lisa W. Heine 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, David Dantzker 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, David Dantzker 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, David Dantzker 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, David Dantzker 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, David Dantzker 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Teryl Sides 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Teryl Sides 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Teryl Sides 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Teryl Sides 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John D. Manders 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John D. Manders 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John D. Manders 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John D. Manders 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, John D. Manders 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Charles Olson 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 02, Charles Olson 2025-11-19. Form 4, filed 2025-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
Section 06, 2025 vote. Form 8-K, filed 2025-02-10. Item 5.07 · say-on-pay result. As reported: 87.66% (votes for as printed: 7,415,339). View filing ↗
Section 06, 2024 vote. Form 8-K, filed 2024-02-12. Item 5.07 · say-on-pay result. As reported: 93.65% (votes for as printed: 9,588,433). View filing ↗
Section 06, 2023 vote. Form 8-K, filed 2023-02-13. Item 5.07 · say-on-pay result. As reported: 94.34% (votes for as printed: 11,173,618). View filing ↗
Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
Section 09b board cost (computed). Computed. Cash 366,250 + equity 292,000 + all other 0 = 658,250, summed across the director compensation table rows.
AtriCure, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in AtriCure, Inc.'s own proxy. As printed: 9,217,620. View filing ↗
AxoGen, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in AxoGen, Inc.'s own proxy. As printed: 9,047,454. View filing ↗
SI-Bone, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in SI-Bone, Inc.'s own proxy. As printed: 7,453,235. View filing ↗
Cutera, Inc., Section 10b CEO total. DEF 14A, filed 2024-06-17. CEO total compensation as printed in Cutera, Inc.'s own proxy. As printed: 7,279,813. View filing ↗
Artivion Inc., Section 10b CEO total. DEF 14A, filed 2026-04-01. CEO total compensation as printed in Artivion Inc.'s own proxy. As printed: 6,883,108. View filing ↗
OraSure Technologies, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in OraSure Technologies, Inc.'s own proxy. As printed: 4,292,228. View filing ↗
Cerus Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Cerus Corporation's own proxy. As printed: 3,794,657. View filing ↗
LeMaitre Vascular, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-14. CEO total compensation as printed in LeMaitre Vascular, Inc.'s own proxy. As printed: 3,780,990. View filing ↗
Surmodics Inc (subject), Section 10b CEO total. DEF 14A, filed 2024-12-19. CEO total compensation as printed in Surmodics Inc's own proxy. As printed: 3,665,496. View filing ↗
Pulmonx Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Pulmonx Corporation's own proxy. As printed: 3,543,520. View filing ↗
Tactile Systems Technology, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-25. CEO total compensation as printed in Tactile Systems Technology, Inc.'s own proxy. As printed: 3,466,916. View filing ↗
NeuroPace, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-21. CEO total compensation as printed in NeuroPace, Inc.'s own proxy. As printed: 2,408,566. View filing ↗
Anika Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Anika Therapeutics Inc.'s own proxy. As printed: 2,033,370. View filing ↗
Xtant Medical Holdings, Inc., Section 10b CEO total. DEF 14A, filed 2026-06-23. CEO total compensation as printed in Xtant Medical Holdings, Inc.'s own proxy. As printed: 1,351,676. View filing ↗
Atrion Corp., Section 10b CEO total. DEF 14A, filed 2024-04-09. CEO total compensation as printed in Atrion Corp.'s own proxy. As printed: 924,464. View filing ↗
Section 10a, Anika Therapeutics Inc. reciprocity. DEF 14A. Anika Therapeutics Inc. names Surmodics Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, LeMaitre Vascular, Inc. reciprocity. DEF 14A. LeMaitre Vascular, Inc. names Surmodics Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
Section 10a, Tactile Systems Technology, Inc. reciprocity. DEF 14A. Tactile Systems Technology, Inc. names Surmodics Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗